Ariel: Antagonizing pain
Although standard of care treatments raise safety concerns, along with high rates of non-responders, the pipeline for acute pain continues to be short on novel targets. Ariel Pharmaceuticals Inc. is developing an in-licensed PTGER4 antagonist...
